蝴蝶中文综合娱乐网2-最好看十大无码AV-成人亚洲精品久久久久软件-日产精品码2码三码四码区-51精品国自产在线-好看AV中文字幕在线观看-久久AV国产麻豆HD真实-一二三四社区在线中文视频

2017-至　 今：中國(guó)科學(xué)院上海營(yíng)養(yǎng)與健康研究所，研究員
2015-2016年：中國(guó)科學(xué)院上海生命科學(xué)研究院/上海交通大學(xué)醫(yī)學(xué)院健康科學(xué)研究所-上海長(zhǎng)征醫(yī)院聯(lián)合轉(zhuǎn)化醫(yī)學(xué)中心，研究員
2007-2015年：美國(guó)哈佛大學(xué)醫(yī)學(xué)院/布萊根婦女醫(yī)院病理系博士后、高級(jí)研究科學(xué)家、講師
1999-2007年：復(fù)旦大學(xué)上海醫(yī)學(xué)院分子醫(yī)學(xué)教育部重點(diǎn)實(shí)驗(yàn)室助教、講師、副教授
2001-2007年：復(fù)旦大學(xué)上海醫(yī)學(xué)院，生物化學(xué)與分子生物學(xué)，博士
1994-1999年：上海醫(yī)科大學(xué)，藥理學(xué)，學(xué)士
　　

消化道腫瘤惡性演變的分子機(jī)制及治療策略

　　腫瘤是一類由基因突變導(dǎo)致的遺傳性疾病，本實(shí)驗(yàn)室主要解析人類惡性腫瘤演變的分子遺傳學(xué)機(jī)制，為這些致死性腫瘤的早期診斷和治療提供新型策略。主要的研究方向有：
　　1. 肉瘤（間葉細(xì)胞來源惡性腫瘤）演變的分子機(jī)制；
　　2. KRAS突變癌（胰腺癌、肺癌等）演變的分子機(jī)制；
　　3. 整合多組學(xué)大數(shù)據(jù)分析與人工智能；
　　4. 新型診斷試劑及抗腫瘤藥物的研制。
　　

1. Xiong Y^#, Wang X^#, Yan K^#, Xin N, Li W, Zhang Z, Cheng Y, Zeng C, Luo Y, Liu X, Lu X, Yan X, Lan H, Wu T, Dong Y, Lin X, Li Y, Jia X, Wang S, Tang H*, Wang Y*. Epithelial plasticity shapes intratumoral heterogeneity and cell lineages in early-stage lung cancer. Sci Adv doi:10.1126/sciadv.ady8546.
2. Cheng Y, Lan H, Lu X, Zeng C, Dong Y, Shen Y, Luo Y, Xiong Y, Wang X, Cui J, Hou L, Jia X, Cao H, Wang S*, Wang M*, Wang Y*. Integrated screens identify AURKB dependency in advanced gastrointestinal stromal tumors. J Exp Med 2025; 222(11):e20250256.
3. Zeng C, Wang Y*. Exploring the cancer immune epigenome by ATAC-seq. Methods Mol Bio 2025; 2930:219-227.
4. Xie F^#, Luo S^#, Liu D^#, Lu X^#, Wang M^#, Liu X^#, Jia F^#, Pang Y, Shen Y, Zeng C, Ma X, Tang D, Tu L, Ni B, Luo Y, Xie F, Hou H, Huang T, Yang L, Zhuang C, Zhao W, Li K, Zheng X, Bi W, Jia X, He Y, Wang S*, Cao H*, Wu K*, Wang Y*. Genomic and Transcriptomic Landscape of Human Gastrointestinal Stromal Tumors. Nat Commun 2024;15(1):9495.
5. Wang S, Xiong Y, Luo Y, Shen Y, Zhang F, Lan H, Pang Y, Wang X, Li X, Zheng X, Lu X, Liu X, Cheng Y, Wu T, Dong Y, Lu Y, Cui J, Jia X, Yang S, Wang L*, Wang Y*. Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma. EMBO Mol Med 2024;16(5):1115-1142.
6. Zheng X^#, Luo Y^#, Xiong Y^#, Liu X, Zeng C, Lu X, Wang X, Cheng Y, Wang S, Lan H, Wang K, Weng Z, Bi W, Gan X, Jia X, Wang L*, Wang Y*. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway. J Immunother Cancer 2023;11(12):e007678.
7. Li K^#, Zheng X^#, Tang H^#, Zang Y^#, Zeng C, Liu X, Shen Y, Pang Y, Wang S, Xie F, Lu X, Luo Y, Li Z, Bi W, Jia X, Huang T, Wei R, Huang K, Chen Z, Zhu Q, He Y, Zhang M, Gu Z, Xiao Y, Zhang X, Fletcher J, Wang Y*. E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer. J Exp Med 2021;218(8):e20210151.
8. Lu X^#, Pang Y^#, Cao H^#, Liu X^#, Tu L, Shen Y, Jia X, Lee JC, Wang Y*. Integrated screens identify CDK1 as a therapeutic target in advanced gastrointestinal stromal tumors. Cancer Res 2021;81(9):2481-2494.
9. Pang Y^#, Xie F^#, Cao H^#, Wang C^#, Zhu M, Liu X, Lu X, Huang T, Shen Y, Li K, Jia X, Li Z, Zheng X, Wang S, He Y, Wang L, Fletcher J*, Wang Y*. Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 2019;116(45):22746-22753. (Direct submission)
   (highlighted by MedicalXpress, The Medical News, Genome Web, Science Codex, Asia-Pacific Biotech News)
10. Cheng Y^#, Jia X^#, Wang Y*. Advance of non-receptor tyrosine kinase targets in the treatment of gastrointestinal stromal tumor. Cancer 2022;42(10):700-707.
11. Liu X^#, Li Z^#, Wang Y*. Advances in targeted therapy and immunotherapy for pancreatic cancer. Adv Biology 2021;5(3):e1900236.
12. Zhou Y^#, Zeng C^#, Sun X^#, Zhang J^#, Qu H^#, Zhang X^#, Zhou Y^#, Liu Z^#, Wu X^#, Wu X^#, Jiao X, Shen L, Zhou Y*, Wang Y*, Li J*. Activity of anlotinib in the second-line therapy of metastatic gastrointestinal stromal tumors: a prospective, multicenter, in vitro study. Oncologist 2023;28(4):e191-e197.
13. Lv Y^#, Tang W^#, Zhang Z^#, Lin Q^#, Luo Y^#, Zheng P, Li K, Jia X, Pang Y, Ji M, Feng Q, He G, Wang Y*, Xu J*. Cullin-9/p53 mediates HNRNPC degradation to inhibit erastin-induced ferroptosis and is blocked by MDM2 inhibition in colorectal cancer. Oncogene 2022;41(23):3210-3221.
14. Zeng C^#, Zhu L^#, Jia X^#, Pang Y^#, Li Z^#, Lu X, Xie F, Duan L, Wang Y*. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors. Gastric Cancer 2020;23(5):837-847.
15. Li Z^#, Shao C^#, Liu X, Lu X, Jia X, Zheng X, Wang S, Zhu L, Li K, Pang Y, Xie F, Lu Y, Wang Y*. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression. Carcinogenesis 2020;41(1):44-55.
16. Guan L, Li Z, Xie F, Pang Y, Zhang C, Tang H, Zhang H, Chen C, Zhan Y, Zhao T, Jiang H, Jia X, Wang Y*, Lu Y*. Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer. J Exp Clin Cancer Res 2020;39(1):53.
17. Chinese expert consensus?on the small gastrointestinal stromal tumors --- clinical practice guidelines in oncology. Chinese Clinical Oncology 2020;25(4):352-358.
18. Wang YX*, Fletcher JA*. Cell cycle and dystrophin dysregulation in GIST. Cell Cycle 2015;14(17):2713-2714.
19. Wang YX, Marino-Enriquez A, Bennett RR, Zhu MJ, Shen YP, Eilers G, Lee JC, Fletcher BS, Gu ZZ, Fox EA, Antonescu CR, Fletcher CDM, Guo XQ, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet 2014;46(6):601-606.
    (highlighted by "Laboratory Investigation", "Modern Pathology" and "BioWorld Today", featured in "Cancer Discovery" Research Watch and selected as one of the most popular stories on nature.com)
20. Serrano C^#, Wang YX^#, Marino-Enriquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA. KRAS and KIT gatekeeper mutations confer polyclonal primary imatinib resistance in GIST: Relevance of concomitant PI3K/AKT dysregulation. J Clin Oncol 2015;33(22):e93-96. (^#Both authors contributed equally)
21. Zhang X^#, Mao T^#, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Ge W, Li S, Yue M, Ma J, Yao J, Wang Y, Wang Y, Shentu D, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L*, Wang L* Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. Ebiomedcine 2022;77:103897.
22. Song Z^#, Wang S^#, Lu L^#, Xu J, Zhou Q, Lu W, Tong H, Zhang Y, Liu W, Wang Z, Li W, You Y, Zhang C, Guo X, Luo R, Hou Y, Wang C, Wang Y, Sun L*, Huang H*, Zhou Y*. Lipidomics and transcriptomics differ liposarcoma differentiation characteristics that can be altered by pentose phosphate pathway intervention. Metabolites 2022;12(12):1227.
23. Zhang X, Mao T, Zhang B, Xu H, Cui J, Jiao F, Chen D, Wang Y, Hu J, Xia Q, Li S, Yue M, Ma J, Yao J, Wang Y, Zhang X, Chen S, Bai Y, Wang Y, Zhang X, Liu Q, Sun Y, Fu D, Liu Y, Xiong L, Wang L. Characterization of DNA damage response deficiency in pancreatic cancer patients from China. Cancer Commun (Lond) 2022;42(1):70-74.
24. Heinrich M, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S. Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors. Clin Sarcoma Res 2019;9:3.
25. Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Marino-Enriquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA. MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun 2017;8:14674.
26. Chen W, Kuang Y, Qiu HB, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, Ou WB. Dual targeting of Insulin Receptor and KIT in imatinib-resistant gastrointestinal stromal tumors. Cancer Res 2017;77(18):5107-5117.
27. Wang Y, Yan X, Mi S, Li Z, Wang Y, Zhu H, Sun X, Zhao B, Zhao C, Zou Y, Hu K, Ding X, Sun A, Ge J. Naoxintong attenuates ischaemia/reperfusion injury through inhibiting NLRP3 inflammasome activation. J Cell Mol Med 2017;21(1):4-12.
28. Wang Q, Liu F, Wang B, Zou F, Chen C, Liu X, Wang A, Qi S, Wang W, Qi Z, Zhao Z, Hu Z, Wang W, Wang L, Zhang S, Wang Y, Liu J, Liu Q. Discovery of N-(3-((1- Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide(CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors. J Med Chem 2016;59(8):3964-3979.
29. Maynard MA, Marino-Enriquez A, Fletcher JA, Dorfman DM, Raut CP, Yassa L, Guo C, Wang Y, Dorfman C, Feldman HA, Frates MC, Song H, Jugo RH, Taguchi T, Hershman JM, Larsen PR, Huang SA. Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med 2014;370(14):1327-1334.
30. Marino-Enriquez A, Ou WB, Cowley G, Luo B, Jonker AH, Mayeda M, Okamoto M, Eilers G, Czaplinski JT, Sicinska E, Wang Y, Taguchi T, Demetri GD, Root DE, Fletcher JA. Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene 2014;33(14):1872-1876.
31. Lynn M, Wang Y, Slater J, Shah N, Conroy J, Ennis S, Morris T, Betts DR, Fletcher JA, O'Sullivan MJ. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma. Diagn Mol Pathol 2013;22(2):76-84.
32. Ravegnini G, Marino-Enriquez A, Slater J, Eilers G, Wang Y, Zhu M, Nucci MR,George S, Angelini S, Raut CP, Fletcher JA. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol 2013;26(5):743-749.
33. Lee CH, Ou WB, Marino-Enriquez A, Zhu M, Mayeda M, Wang Y, Guo X, Brunner AL, Amant F, French CA, West RB, McAlpine JN, Gilks CB, Yaffe MB, Prentice LM, McPherson A, Jones SJ, Marra MA, Shah SP, van de Rijn M, Huntsman DG, Dal Cin P, Debiec-Rychter M, Nucci MR, Fletcher JA. 14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci U S A 2012;109(3):929-934.
34. Zhang LF, Gui YH, Wang YX, Jiang Q, Song HY. Effect of Tbx1 knock-down on cardiac performance in zebrafish. Chin Med J 2010;123(9):1182-1189.
35. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ,Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, CorsoG, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, MeyersonML, Garraway LA. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009;4(11):e7887.
36. Jiang Q, Liu D, Gong Y, Wang Y, Sun S, Gui Y, Song H. yap is required for the development of brain, eyes, and neural crest in zebrafish. Biochem Biophys Res Commun 2009;384(1):114-119.
37. Sun S, Gui Y, Wang Y, Qian L, Liu X, Jiang Q, Song H. Effects of methotrexate on the developments of heart and vessel in zebrafish. Acta Biochim Biophys Sin 2009;41(1):86-96.
38. Xu H, Yang J, Wang Y, Jiang Q, Chen H, Song H. Exposure to 17alpha-ethynylestradiol impairs reproductive functions of both male and female zebrafish. Aquat Toxicol 2008;88(1):1-8.
39. Sun SN, Gui YH, Wang YX, Qian LX, Jiang Q, Liu D, Song HY. Effect of dihydrofolate reductase gene knock-down on the expression of heart and neural crest derivatives expressed transcript 2 in zebrafish cardiac development. Chin Med J 2007;120(13):1166-1171.
40. Zhang L, Zhong T, Wang Y, Jiang Q, Song H, Gui Y. TBX1, a DiGeorge syndrome candidate gene, is inhibited by retinoic acid. Int J Dev Biol 2006;50(1):55-61.
41. Qian LX, Wang YX, Jiang Q, Zhong TP, Song HY. Ethanol disrupts the formation of hypochord and dorsal aorta during the development of embryonic zebrafish. Sci China C Life Sci 2005;48(6):608-615.
42. Wang YX, Qian LX, Dong YX, Yao LL, Gui YH, Zhong TP, Song HY. Bone Morphogenetic Protein-2 acts upstream of Myocyte-specific Enhancer Factor 2A to control embryonic cardiac contractility. Cardiovasc Res 2007;74(2):290-303.
43. Wang YX, Qian LX, Jiang Q, Dong YX, Gui YH, Zhong TP, Song HY. Myocyte-specific enhancer factor 2A is essential for zebrafish posterior somite development. Mech Dev 2006;123(10):783-791.
44. Wang YX, Qian LX, Yu Z, Jiang Q, Dong YX, Liu XF, Yang XY, Zhong TP, Song HY. Requirements of myocyte-specific enhancer factor 2A in zebrafish cardiac contractility. FEBS Lett 2005;579(21):4843-4850.
45. Wang Y, Zhong T, Qian L, Dong Y, Jiang Q, Tan L, Song H. Wortmannin induces zebrafish cardia bifida through a mechanism independent of phosphoinositide 3-kinase and myosin light chain kinase. Biochem Biophys Res Commun 2005;331(1):303-308. (Cover Photo)
46. Wang YX, Song HY. Developmental genetics of zebrafish cardiovascular systems. Section Genet Foreign Med Sci 2004;27(4):220-223.
47. Wang YX, Yang J, Ma CG, Yang XY, Song HY. VEGF₁₂₁ cDNA gene transfer and expression in Vitro. Prog Biochem Biophys 2003;30(4):612-616.
48. Wang YX, Guan XQ, Yang J, Mo W, Song HY. Molecular Cloning, Expression and characterization of recombinant human vascular endothelial growth factor 121. Prog Biochem Biophys 2002;29(3):444-448.